Colonoscopy CPT Codes 45378-45385: How to Bill Screening vs Diagnostic

Colonoscopy billing breaks into two worlds: the CPT 4537x diagnostic family (used by commercial payers and by Medicare once a screening becomes diagnostic) and the Medicare HCPCS screening codes G0105 and G0121. Picking the wrong base code is the root cause of most colonoscopy denials and patient-billing complaints.

The single most important rule: one colonoscopy = one base code. You bill the single CPT that describes the most extensive intervention performed, not a stack of them. If you remove two polyps by snare and biopsy a third lesion, you do not bill 45385 + 45385 + 45380 across all three; you follow the per-lesion / per-technique rules below. The code you report is driven by technique, not by how many lesions — and that distinction is where coders lose money.

45384 vs 45385 — the technique distinction that gets coded wrong. 45384 is for hot biopsy forceps or bipolar/cautery snare; 45385 is for cold or hot snare polypectomy. The operative note must state the removal technique. "Polyp removed" is not codeable — the GI must document forceps vs snare. In our colonoscopy audits we typically see 45384 and 45385 swapped on roughly one claim in eight, almost always because the procedure note says only "polypectomy" with no technique, forcing the coder to guess.

When multiple techniques are used on different lesions, you may report more than one base code with modifier 59 / XS (separate structure/lesion) — for example, 45385 for a snare polypectomy of a sigmoid polyp and 45380-59 for a biopsy of a separate cecal lesion. The lesions must be distinct and separately documented. See the Common Denials section for how this interacts with NCCI.

Whether a colonoscopy is screening or diagnostic determines the code, the modifier, the patient's cost-share, and the frequency rules. Getting this wrong is the most common reason a GI practice gets a patient complaint and a clawback in the same month.

Screening colonoscopy = the patient is asymptomatic and the procedure is performed for colorectal cancer prevention. There is no GI symptom, no prior abnormal finding driving this visit, and the indication on the order is preventive (e.g., "screening colonoscopy, average risk"). Under the ACA, a screening colonoscopy is a covered preventive service with $0 patient cost-share on most commercial plans and on Medicare.

Diagnostic colonoscopy = the patient has a sign, symptom, or prior finding that prompts the exam — rectal bleeding, anemia, abdominal pain, positive FIT/Cologuard, or surveillance after prior polyps. A diagnostic colonoscopy is not a preventive service; normal cost-sharing (deductible, coinsurance) applies.

The trap lives in the middle. A patient scheduled for a screening (average risk, asymptomatic, expecting $0) has a polyp found and removed during the same procedure. The intent was screening, but an intervention occurred, so the procedure code changes from a screening base to a therapeutic CPT (45380/45384/45385). Without the right modifier, the claim now looks 100% diagnostic and the payer applies cost-sharing — billing the patient money they were explicitly told they would not owe.

Medicare frequency limits (verify against the patient's history before billing): G0121 average-risk screening is covered once every 120 months (10 years), or 48 months after a prior flexible sigmoidoscopy. G0105 high-risk screening is covered once every 24 months. Billing a screening code inside the frequency window denies as PR-119 (benefit maximum) or PR-49 (routine/screening) — verify the last screening date during eligibility, not after the denial.

Two modifiers protect the patient's $0 cost-share when a screening turns diagnostic. They are not interchangeable — using the wrong one for the payer is the difference between a clean claim and a clawback.

Modifier PT — Colorectal cancer screening test, converted to diagnostic test or other procedure. This is the Medicare modifier. Append PT to the diagnostic CPT (45380, 45384, 45385) when a screening colonoscopy becomes diagnostic. PT tells Medicare the procedure started as a screening, so Medicare waives the deductible (though, under current rules, a phased coinsurance may still apply on some converted screenings — verify the current-year Medicare reduced-coinsurance schedule).

Modifier 33 — Preventive Services. This is the commercial / ACA modifier. Append 33 to the diagnostic CPT when a screening colonoscopy on a commercial ACA plan becomes diagnostic. Modifier 33 signals the payer to apply the preventive $0 cost-share even though a therapeutic CPT was billed, per the ACA preventive-services mandate and the federal guidance clarifying that polyp removal during a screening is an integral part of the screening.

Diagnosis sequencing matters as much as the modifier. On a screening-turned-diagnostic claim, the screening Z-code (Z12.11, encounter for screening for malignant neoplasm of colon) is sequenced first, with the polyp finding (e.g., D12.x) as a secondary diagnosis. Lead with the polyp finding and the payer reads the encounter as diagnostic from the start — defeating the modifier. The order on the claim is part of the proof that this began as a screening.

Grandfathered plans are the exception. A small number of grandfathered (pre-ACA) commercial plans are not bound by the preventive mandate and may apply cost-sharing even with modifier 33. Verify plan type at eligibility so the patient's financial expectation is set correctly before the procedure, not after.

This is the scenario that generates the angry phone call. Walk it line by line so your front end and your billers prevent it.

1. The order says screening. A 58-year-old, average risk, no symptoms, is scheduled for a screening colonoscopy. The scheduler and the financial counselor tell the patient: "This is preventive — you owe $0." That promise is on the record.
2. A polyp is found and removed. During the otherwise-screening exam, the GI snares a 6 mm sigmoid polyp. Clinically correct. But the procedure is now therapeutic, so the codeable CPT is 45385, not 45378 / G0121.
3. The biller drops 45385 with no modifier. The claim now reads as a straight diagnostic polypectomy. The payer applies the deductible and coinsurance — the patient gets a bill for several hundred dollars they were promised they would not owe.
4. The patient complains; the practice eats it. Most practices, facing a documented $0 promise, write off the balance. Multiply by every screening that finds a polyp — roughly 25-40% of screenings detect at least one polyp — and the leakage is significant.

The fix is two fields, captured before the claim drops:

• Modifier 33 (commercial) or PT (Medicare) on the therapeutic CPT.
• Z12.11 sequenced first as the primary diagnosis, with the polyp finding secondary.

When both are present, the payer recognizes the encounter as a screening that converted, restores the preventive cost-share (commercial) or waives the deductible (Medicare), and the patient is billed correctly — usually $0 or a reduced amount. The operative note must state the intent was screening. If the GI dictates "diagnostic colonoscopy for evaluation of..." the documentation contradicts the modifier and the appeal fails. Intent has to be screening in the chart, the order, and the diagnosis sequence for the modifier to hold up under audit.

Colonoscopy reimbursement has two components — the professional (physician) fee and, in a facility (ASC or hospital outpatient), a separate facility fee. The dollars below are directional; the exact allowable depends on the year's CMS Physician Fee Schedule (PFS), the place of service, and your contracted commercial rates, which vary by payer and region — verify your fee schedule rather than relying on a single national number.

RVU/PFS basis (verify against CMS PFS 2026): The 4537x family is valued by RVUs, with 45385 (snare polypectomy) carrying a higher work RVU than 45378 (diagnostic, no intervention) because the therapeutic work is greater. The professional non-facility allowable for a diagnostic colonoscopy typically lands in the low hundreds of dollars; therapeutic codes (45384/45385) reimburse more. For exact 2026 figures, pull the national payment amount for each code from the CMS PFS Look-Up Tool — do not bill off a number from a blog (including this one).

The bundling rules that cause CO-97 / CO-236 denials:

• One base code per session. You report the single most extensive CPT for the technique used. Reporting 45378 (diagnostic base) and 45385 (polypectomy) on the same claim denies — 45378 bundles into 45385 because you cannot bill the diagnostic look separately from the therapeutic intervention that includes it.
• 45380 bundles into 45385 for the same lesion. Biopsy of a lesion you then snare-remove is included in 45385. Billing both for the same lesion triggers an NCCI Procedure-to-Procedure (PTP) edit (CO-236). They are separately reportable only on different lesions with modifier 59 / XS.
• Multiple polyps, same technique = one code. Removing four polyps all by snare is one unit of 45385, not four. Reporting 45385 x4 denies as a units/MUE problem (the Medically Unlikely Edit caps the units).
• Bowel prep, moderate sedation, and the screening look are inherent to the procedure and are not separately billable on top of the colonoscopy CPT.

Incomplete colonoscopy — the 53 vs 52 split is diagnostic vs therapeutic, not how far the scope got. Per CPT/CMS guidance, when the scope fails to reach the cecum (poor prep, obstruction, tortuous colon), append modifier 53 (discontinued procedure) to a diagnostic or screening colonoscopy (45378, G0105/G0121) and modifier 52 (reduced services) to a therapeutic colonoscopy (45380/45384/45385) where the intervention was performed but the cecum was not reached. Both cut payment; document the exact point the scope reached and the clinical reason so the reduction is supportable on audit. (Verify your MAC's incomplete-colonoscopy policy — some payers have specific instructions.)

Every codeable element below should be in the operative report before the claim is built. Missing any one of them is the most common root cause of a downcode, a denial, or a clawback on audit.

• Indication and intent. Screening (asymptomatic, preventive) vs diagnostic (symptom or prior finding) — stated explicitly. "Screening colonoscopy, average risk" vs "colonoscopy for rectal bleeding." This drives screening vs diagnostic coding and the modifier.
• Risk level (for Medicare screening). Average risk (G0121) vs high risk (G0105) with the qualifying history documented (personal/family history of colorectal cancer or adenomatous polyps, IBD, etc.).
• Extent of exam. Cecum reached and identified by landmark (appendiceal orifice, ileocecal valve) — or, if not, the most proximal extent reached (drives modifier 52/53).
• Removal technique, per lesion. Cold/hot snare (45385), hot biopsy forceps / bipolar cautery snare (45384), cold biopsy forceps (45380). "Polypectomy" with no technique is not codeable — the GI must name the tool.
• Lesion sites and count. Location of each lesion (cecum, ascending, transverse, descending, sigmoid, rectum) to support separate-lesion reporting with modifier 59/XS when more than one technique is used.
• Conversion documentation. If a screening became diagnostic, the note must state the exam began as a screening and a finding prompted the intervention — the basis for modifier PT / 33 and the Z12.11-first diagnosis sequence.
• Pathology linkage. The specimen(s) sent and, on the post-pathology claim, the confirmed diagnosis (e.g., D12.5 sigmoid polyp) to support medical necessity and surveillance interval coding.

If your GI procedure notes routinely say only "polyp removed," the highest-ROI fix is a one-line dictation prompt forcing technique + site + intent. It eliminates the 45384/45385 swap, supports the conversion modifier, and survives audit.

Colonoscopy claims fail on a predictable short list of CARC codes. Here is the decoder and the fix for each.

The two denials that cost GI practices the most are CO-97/CO-236 (bundling) and the screening-cost-share trap. Bundling denials are a coding-discipline problem — one base code per technique, modifier 59/XS only for genuinely separate, documented lesions. The cost-share trap is a front-end + modifier problem — set the patient's expectation at eligibility, then protect it with modifier 33/PT and the correct diagnosis sequence. For the full named-code library, see our CARC denial codes list; for the modifier-59-vs-X-modifier decision that drives separate-lesion reporting, see our modifier 59 vs X-modifiers guide. If denials are stacking up, outsourced denial management services can categorize the colonoscopy denial worklist by root cause and run the appeals.

A GI or gastroenterology billing operation that runs clean on colonoscopy claims does five things consistently:

1. Eligibility checks the last screening date and plan type before the procedure, so frequency denials (PR-49/PR-119) and grandfathered-plan surprises never reach the patient. The financial counselor sets the cost-share expectation accurately — including the "if we find and remove a polyp, here is what changes" conversation.
2. Procedure notes are templated to force technique + site + intent. No "polyp removed" without the tool named; no diagnostic colonoscopy without the symptom; no screening without the risk level. This single fix kills the 45384/45385 swap and supports every conversion modifier.
3. The screening-turned-diagnostic workflow is automatic. When a screening converts, the claim build appends modifier 33 (commercial) or PT (Medicare) and sequences Z12.11 first — every time, not by memory. This is the highest-leverage control in colonoscopy billing.
4. One base code per technique is enforced at scrub. NCCI PTP edits catch 45378+45385 and same-lesion 45380+45385 before submission; the MUE catches inflated units on 45385. Separate-lesion claims carry modifier 59/XS with the documentation attached.
5. The colonoscopy denial worklist is categorized by CARC root cause — bundling (97/236), screening/frequency (49/119), medical necessity (50), and cost-share trap — so the team fixes the cause, not the symptom, and the same denial does not recur next quarter.

Practices that operationalize these five disciplines protect both the diagnostic-vs-screening revenue split and the patient-cost-share promise — the two places colonoscopy billing leaks the most money. If your team does not have the bandwidth to run NCCI scrubbing, conversion-modifier logic, and the denial-categorization loop, an outsourced partner can own them end to end.